Diketo-Piperazine and Piperidine derivatives as antiviral agents
This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with diketo piperazine and piperadine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.
1. A compound which is selected from the group consisting of:
2. A compound which is selected from the group consisting of:
3. A compound which is selected from the group consisting of:
4. A compound which is selected from the group consisting of:
5. A pharmaceutical composition which comprises an antiviral effective amount of a compound of claim 1 , or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, excipients or diluents.
6. A pharmaceutical composition which comprises an antiviral effective amount of a compound of claim 2 , or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, excipients or diluents.
7. A pharmaceutical composition which comprises an antiviral effective amount of a compound of claim 3 , or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, excipients or diluents.
8. A pharmaceutical composition which comprises an antiviral effective amount of a compound of claim 4 , or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, excipients or diluents.
9. The composition of claim 5 , further comprising a second compound having anti-HIV activity.
10. The composition of claim 6 , further comprising a second compound having anti-HIV activity.
11. The composition of claim 7 , further comprising a second compound having anti-HIV activity.
12. The composition of claim 8 , further comprising a second compound having anti-HIV activity.
13. A method for treating a mammal infected with HIV virus comprising administering to said mammal an antiviral effective amount of a compound of claim 1 , or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, excipients or diluents.
14. A method for treating a mammal infected with HIV virus comprising administering to said mammal an antiviral effective amount of a compound of claim 2 , or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, excipients or diluents.
15. A method for treating a mammal infected with HIV virus comprising administering to said mammal an antiviral effective amount of a compound of claim 3 , or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, excipients or diluents.
16. A method for treating a mammal infected with HIV virus comprising administering to said mammal an antiviral effective amount of a compound of claim 4 , or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable carriers, excipients or diluents.
17. The method of claim 13 , comprising administering to said mammal an antiviral effective amount of said compound in combination with an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: an AIDS antiviral agent; an anti-infective agent; an immunomodulator; and an HIV entry inhibitor.
18. The method of claim 14 , comprising administering to said mammal an antiviral effective amount of said compound in combination with an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: an AIDS antiviral agent; an anti-infective agent; an immunomodulator; and an HIV entry inhibitor.
19. The method of claim 15 , comprising administering to said mammal an antiviral effective amount of said compound in combination with an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: an AIDS antiviral agent; an anti-infective agent; an immunomodulator; and an HIV entry inhibitor.
20. The method of claim 16 , comprising administering to said mammal an antiviral effective amount of said compound in combination with an antiviral effective amount of an AIDS treatment agent selected from the group consisting of: an AIDS antiviral agent; an anti-infective agent; an immunomodulator; and an HIV entry inhibitor.
21. The compound of claim 1 , wherein said compound is selected from the group
22. The compound of claim 2 , wherein said compound is